Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) on August 5, 2026. The report covers an event occurring on the same date involving the company's wholly-owned subsidiary, Citius Oncology, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement.
Material Changes
The primary material event reported is an update regarding the expanding base of institutional accounts ordering the company's product, LYMPHIR®. No quantitative changes in financial position are detailed in this document.
Guidance, Outlook, and Management Commentary
Management, represented by Chairman and CEO Leonard Mazur, announced the expansion of institutional accounts for LYMPHIR® via a press release dated August 5, 2026. The full text of this press release is included as Exhibit 99.1. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the announcement of the business development.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the number of new institutional accounts and the nature of the orders.
- Verify the commercial impact of the LYMPHIR® expansion on future revenue projections in subsequent earnings reports.
- Confirm the regulatory status and market acceptance of LYMPHIR® within the newly acquired institutional accounts.